Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial

发表于 2026-9-12 09:53:38

期刊：Nature Cancer

文献作者：Louise Emmett; Mina Swiha; Nathan Papa; Shalini Subramaniam; Megan Crumbaker; Anthony M. Joshua; Andrew Nguyen; Andrew Weickhardt; Sze-Ting Lee; Siobhan Ng; Roslyn J. Francis; Jeffrey C. Goh; David A. Pattison; Sarennya Pathmanandavel; Thomas Hope; Narjess Ayati; Michael S. Hofman; Shahneen Sandhu; Claire Niu; Andrew J. Martin; Hayley Thomas; Martin R. Stockler; Ian D. Davis;

出版日期：--

DOI号：10.1038/s43018-026-01140-3

下载链接：https://www.nature.com/articles/s43018-026-01140-3.pdf

文献链接：https://doi.org/10.1038/s43018-026-01140-3

当前文献来源于 Springer Science and Business Media LLC。

备注信息：

发表于 2026-9-12 09:53:39

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[Nature] Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Nature] Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial 一键复制

已采纳